Form 4: Viemed Healthcare General Counsel Reports Stock Transactions

Viemed Healthcare's General Counsel, Jeremy Trahan, reported the vesting of restricted stock units and phantom shares, along with new equity awards.

Summary

• Jeremy Trahan, General Counsel of Viemed Healthcare, Inc. (VMD), reported changes in his beneficial ownership of company common shares.
• On January 17, 2026, 4,884 common shares were acquired due to the vesting of Restricted Stock Units (RSUs) that were originally granted on January 17, 2023.
• Concurrently, 1,595 common shares were disposed of at a market closing price of $7.33 per share (as of January 16, 2026) to satisfy tax obligations resulting from the RSU vesting.
• Also on January 17, 2026, 1,221 common shares were acquired and simultaneously disposed of at $7.33 per share, representing the cash settlement of phantom shares granted on January 17, 2023.
• Following these transactions, Trahan's direct beneficial ownership of common shares was 28,792.
• On January 19, 2026, Trahan was granted new equity awards consisting of 50,360 Restricted Stock Units and 12,590 Phantom Share Units.
• These newly granted awards are scheduled to vest in three equal annual installments, with the first installment occurring on January 19, 2027, and have an expiration date of January 19, 2029.

Sentiment

Score: 5

Explanation: Neutral. This is a routine Form 4 filing detailing executive compensation and stock transactions, which is neither inherently positive nor negative for the company's immediate outlook.

Positives

• General Counsel Jeremy Trahan received new equity awards totaling 50,360 Restricted Stock Units and 12,590 Phantom Share Units, indicating continued long-term incentive alignment with the company's performance.
• The vesting of previous equity awards demonstrates the company's commitment to its established compensation structure for key executives.

Negatives

• 1,595 common shares were disposed of to satisfy tax obligations, which, while a standard practice, reduces the reporting person's direct share ownership.
• 1,221 common shares were disposed of for the cash settlement of phantom shares, also reducing direct share ownership.

Future Outlook

The new equity awards granted to the General Counsel, vesting over three years, suggest a continued long-term incentive structure for key management, aligning their interests with the company's future performance.

Industry Context

This filing represents a routine insider transaction related to executive compensation, which is a common practice across publicly traded companies in all industries, including healthcare. It does not provide specific insights into Viemed Healthcare's operational performance or competitive position within the healthcare sector.

Stakeholder Impact

• Shareholders: The issuance of new equity awards could lead to minor dilution over time as shares vest, but also aligns management's interests with long-term shareholder value.
• Employees: Reflects the company's ongoing executive compensation practices.

Next Steps

• Future vesting of 50,360 Restricted Stock Units in three equal annual installments starting January 19, 2027.
• Future vesting of 12,590 Phantom Share Units in three equal annual installments starting January 19, 2027.

Key Dates

Keywords

Viemed Healthcare, VMD, SEC Form 4, Insider Trading, Restricted Stock Units, Phantom Shares, Equity Compensation, Jeremy Trahan, General Counsel